A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
← catalyst calendarNCT03633708 · readout in 896 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
56estimated
Sites
43
Countries
Argentina, India, Malaysia +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-29 | actual | When the study began enrolling |
| Primary completion | 2029-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Secondary Hyperparathyroidism
- Chronic Kidney Disease
Interventions
- Drug: Etelcalcetide — also filed as Parsabiv
- Other: Standard of Care
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP)
measured Baseline and Weeks 20-27
Percentage Change from Baseline in Mean iPTH During the EAP
measured Baseline and Weeks 20-27
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed